The transition from low grade astrocytoma to glioblastoma multiforme is almost always accompanied by the loss of genetic markers from chromosome 10. Recently two genes, PTEN/MMAC1/TEP1 and DMBT, have been isolated from chromosome 10q. We have analysed these two genes for mutations in 21 primary glioblastomas. An exon by exon screen of the PTEN gene using SSCP failed to identify any mutations in this tumour series. In contrast, 38% of tumours showed intragenic homozygous deletions in the DMBT gene. The fact that the majority of gliomas do not carry mutations in either of these genes suggests that there may still be other genes on chromosome 10 which are important in the development of glioblastoma multiforme.
Keywords: glioma; PTEN; DMBT; mutation; tumour suppressor; 10q24-26 Glioblastoma multiforme (GBM) is the most common malignant primary tumour of the adult central nervous system. The prognosis for patients suering from these tumours is poor, with a median post treatment survival time of less than 2 years (Louis and Cavenee, 1997) . A number of genetic abnormalities have been correlated with the development of GBMs, perhaps the most striking of which involves chromosome 10 (Bigner et al., 1988 (Bigner et al., , 1990 James et al., 1988; Ransom et al., 1992) . One complete copy of chromosome 10 is lost in 70% of tumours and up to 90% of gliomas show heterozygous deletions involving at least part of chromosome 10. These observations suggest that at least one tumour suppressor gene resides on this chromosome (Steck et al., 1995 (Steck et al., , 1997 . Loss of heterozygosity and microsatellite analysis of those tumours showing only partial deletions of chromosome 10, have identi®ed a more precise location for this putative tumour suppressor gene in the region spanning 10q24-10q26 (Rasheed et al., 1992 (Rasheed et al., , 1995 Fults and Pedone, 1993; Karlbom et al., 1993; Albarosa et al., 1996) . Recently two candidate tumour suppressor genes, PTEN and DMBT, which have been implicated as having a causal role in GBM development, have been cloned and mapped to this chromosomal region Li and Sun, 1997; Steck et al., 1997; Mollenuhauer et al., 1997) .
The PTEN gene encodes a tyrosine or dual speci®c phosphatase (Li and Sun, 1997; Myers et al., 1997) . It is known that many tyrosine kinases are encoded by proto-oncogenes, and therefore, it is thought that genes which encode proteins that counteract their activity, such as the tyrosine phosphatases, may be suppressor genes. For this reason, PTEN was believed to be a good candidate for the chromosome 10q tumour suppressor gene. Mutation analysis demonstrated PTEN mutations in 63% of the glioblastoma cell lines analysed but only 20% of primary GMB tumours . More recently, two studies found the incidence of mutation in PTEN to be 44% and 31% (Rasheed et al., 1997; Wang et al., 1997) . To investigate the incidence of PTEN mutations further we have analysed a random collection of 21 glioblastoma multiforme tumours. Tumour DNA was analysed for mutations by SSCP, using the MDE gel system (FMC BioProducts), in accordance with the manufacturer's instructions. The previously described mutation in the U251 glioma cell line (Steck et al., 1997) was clearly detected on the SSCP gels, however, no other mutations were seen in any of the nine coding exons in the 21 primary tumours analysed.
The absence of PTEN mutations in this unselected series of GBMs was surprising, given the relatively high incidence reported by other groups recently. Since we used SSCP to prescreen exons for mutations, it is possible that this technique is not sensitive enough to detect all mutations. We think this possibility unlikely for a number of reasons: (1) our past experience with a number of dierent genes has found that this is a very successful way of identifying a large percentage of mutations (Hogg et al., 1992 (Hogg et al., , 1993 Baird et al., 1992; Davis and Cowell, 1993; Cowell et al., 1994; Liu et al., 1995) ; (2) the mutation in cell line U251 was readily detectable in our hands; and (3) this approach was also the means used to identify mutations in the previous study by Rasheed et al. (1997) demonstrating that this can be an eective approach. It is possible that the inactivating mutations have been missed as they occur in noncoding regions of PTEN, such as the promotor or introns, however this would dier from previous ®ndings, where the bulk of mutations occurred in exonic regions of the gene. The other explanation, therefore, is that the frequency of mutations in this series is, in fact, extremely low. This may be due to the fact that our series of tumours was unselected in any way other than being GBM. These tumours have not previously been analysed for LOH on chromosome 10 which might have selected for tumours more likely to have mutations in this gene, neither have these tumours been preselected for carrying mutations in other genes such as p53, although a previous report showed no correlation between p53 and PTEN mutations in GBM (Rasheed et al., 1997) . Review of the pathology for all of these tumours con®rmed that they were GBM. We conclude, therefore, that PTEN mutations may not be as frequent in GBM as suggested elsewhere, although clearly larger studies will be needed to establish the true incidence. Interestingly PTEN mutations have also been identi®ed at a higher frequency in prostate and endometrial carcinomas (Kong et al., 1997; , which also show a high incidence of LOH for chromosome 10 markers. Constitutional mutations in PTEN were found in patients with Cowden syndrome and Bannayan-Zonana syndrome . These syndromes are characterized by the development of harmatomas or polyps throughout the body. Although aected individuals have a predisposition to certain cancers including those of the breast, thyroid and GI tract, they do not seem to be particularly susceptible to GBMs. Taken together these data possibly suggest a role for PTEN as a more general tumour suppressor gene rather than one involved speci®cally in the development of glioblastoma multiforme. That PTEN is infrequently involved in GBM development might also have been predicted from the clear association of this gene with the predisposition to two related cancer predisposition syndromes where the aected patients have not been formally shown to have an increased risk for the development of brain tumours. This observation possibly argues against a primary role for this gene in the development of brain tumours. The other important point to bear in mind is that PTEN, in fact, lies outside the minimum region of LOH seen in this large series of tumours, further arguing against its direct role in brain tumorigenesis. Thus, while mutations in PTEN clearly do occur, albeit possibly in the more aggressive tumours and cell lines, they are still absent from the majority of brain tumours suggesting that there are, as yet unidenti®ed, gene(s) in 10q24 which have a more fundamental role in tumorigenesis.
The DMBT (Deleted in Malignant Brain Tumours) gene was isolated by representational dierential analysis and mapped to a region spanning 10q25.3-26.1 (Mollenhauer et al., 1997) . At the amino acid level, this gene has homology to members of the scavenger receptor cystein rich family (SCRC). Initial analysis of DMBT using a series of PCR primer pairs from within the genomic locus (Figure 1 ) resulted in the identi®cation of intragenic homozygous deletions within this gene in a number of tumours including gliomas. In the initial study of 39 patients with glioblastoma multiforme, intragenic homozygous deletions were detected in 23% of cases. To determine whether any of the GBMs in our series showed DMBT deletions, all 21 tumours that had been examined for PTEN mutations, were screened for homozygous deletions by PCR using the primers described by Mollenhauer et al. (1997) . Homozygous, intragenic deletions were detected in eight of the 21 (38%) tumours screened (Figure 2 ). While only one marker was deleted in most tumours, in CCF 4, homozygous deletion of two markers (g14ext and 60k) was observed. In this particular tumour the intervening g14 locus was not deleted suggesting that as more complex rearrangement has occurred in this tumour. Cytogenetic analysis of this tumour has previously shown that one copy of chromosome 10 is completely missing and the remaining 10q24-25 region is nonreciprocally translocated into the pericentromeric long arm of chromosome 11 (Chernova and Cowell, 1998) . Although a detailed analysis of this rearrangement is beyond the scope of this study, the preliminary FISH analysis suggests that one of the translocation breakpoints lies in the vicinity of the DMBT gene. In studies reported so far, only homozygous intragenic deletions of DMBT have been analysed. It is possible that the true incidence of mutations have been underestimated Figure 2 PCR analysis of the DMBT locus using primers that amplify the markers g14, g14extf, 36k, 60k, 74k and 101n (see Figure 1 ). 17 primary GBMs and 4 primary cultures (CCF 3, 4 30 and 31) were analysed. A control set of primers (c12), which amplify an unrelated chromosome 8-speci®c marker, were used to demonstrate that the PCR reactions were working properly. Homozygous deletions are seen for markers 74k, g14extf and 60k. The primers used to amplify the 101n locus produced a nonspeci®c (lower) band in our hands and that other tumours may carry more subtle inactivating mutations within the gene. In order to investigate this possibility, the genomic structure and sequence of the gene will be required. Thus, in our series, deletions within the DMBT gene appear to be far more common than are mutations in PTEN.
In summary, we have screened two putative tumour suppressor genes for inactivating mutations or deletions in GBMs. One gene, PTEN, contained no exonic mutations, whereas only 38% of primary GBMs contained homozygous intragenic deletions in DMBT, leaving the genetic cause of tumorigenesis uncertain in the majority of patients. It is therefore possible that some, as yet unidenti®ed, tumour suppressor gene(s) is the primary target for loss of the heterozygosity on chromosome 10q and not PTEN and DMBT.
